Transcriptomic profiling of glioblastoma cells treated with the FGFR inhibitor erdafitinib
Glioblastoma (GBM) is the most aggressive primary malignant brain tumor with limited therapeutic options. This project investigates transcriptomic changes in glioblastoma cells following treatment with erdafitinib, a selective fibroblast growth factor receptor (FGFR) inhibitor. RNA sequencing was performed to identify differentially expressed genes and molecular pathways associated with erdafitinib response in glioblastoma cells. The generated sequencing data provide resources for understanding the mechanisms underlying FGFR-targeted therapy in GBM.